Pr
Prometheus (Merck)
San Diego CAFounded 2016250 employees
Private CapbiotechAcquiredImmunologyGI
Platform: TL1A
Market Cap
N/A
All Drugs
3
Clinical Trials
4
Failed / Terminated
2
FDA Approved
0
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Zoribrutinib | PRO-6769 | Phase 1/2 | 1 | DLL3 | MCLMigraine | ||
| Olpazasiran | PRO-8626 | Preclinical | 2 | DLL3 | ADHDTTR Amyloidosis | ||
| Niraratamab | PRO-4156 | Phase 2 | 1 | B7-H3 | MDDGBM |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (4)